Werewolf Therapeutics Takes Aim At Untapped Pain Market With Ambros Deal
Werewolf Therapeutics and Ambros Therapeutics merge in an all-stock deal with $150M in financing to advance Phase 3 CRPS-1 candidate.
Two smaller medicine companies joined together and got $150 million to help develop a new pain treatment they've been testing. When companies merge and get new money, it shows they believe in their product and want to grow—that's something to watch as a sign of their confidence.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.